Seres Therapeutics (MCRB) Misses Q3 EPS by 6c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.38), $0.06 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hub Group faces credibility test as Q2 report looms Sept. 1
• AiRWA receives Nasdaq deficiency notice over late 10-K filing